AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Shares Shorted: Short Interest Down 49.1% in September

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 1,407,198 shares, a decrease of 49.1% from the September 15th total of 2,765,187 shares. Based on an average daily volume of 1,866,131 shares, the days-to-cover ratio is currently 0.8 days. Approximately 4.7% of the company’s stock are sold short.

AIM ImmunoTech Stock Up 5.3%

AIM traded up $0.01 on Thursday, reaching $0.17. The company’s stock had a trading volume of 1,024,287 shares, compared to its average volume of 11,667,928. The company has a market capitalization of $5.18 million, a price-to-earnings ratio of -0.05 and a beta of 1.27. AIM ImmunoTech has a fifty-two week low of $0.16 and a fifty-two week high of $2.88. The stock has a 50 day moving average of $0.22 and a two-hundred day moving average of $0.34.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its earnings results on Friday, August 7th. The company reported ($0.43) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter. As a group, analysts anticipate that AIM ImmunoTech will post -0.78 earnings per share for the current fiscal year.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc is a clinical-stage immuno-pharmaceutical company focused on developing therapies that activate and regulate the immune system. The company’s research programs target cancer, viral diseases and other conditions in which immune-system activity may play a role in disease progression or treatment response.

AIM’s principal investigational product is Ampligen (rintatolimod), a double-stranded RNA-based immune modulator designed to stimulate antiviral and antitumor immune responses.